Clinical Trial Communications

---

January 5, 2022

NIAID Letter to Mix & Match Trial Participants

We now have early results from the participants who received their original COVID-19 vaccine regimen before they joined the study, then got a COVID-19 booster dose during the trial of either the Moderna vaccine (standard 100 mcg dose), the Janssen vaccine, or the Pfizer-BioNTech vaccine.

---

December 20, 2021

Novavax Letter to PREVENT-19 Trial Participants

We remain sincerely grateful for your participation in the PREVENT-19 clinical trial and your significant contribution to medical research addressing COVID-19. We are writing to provide an update on Novavax’ COVID-19 vaccine program. Foremost is the exciting news that the Novavax COVID-19 vaccine demonstrated high level efficacy in our PREVENT-19 Phase 3 trial in the U.S. and Mexico.

---